Qu Linda C, Istl Alexandra C, Tang Elaine, Chaulk Richard C, Gray Daryl
Western University, London, ON, Canada.
Medical College of Wisconsin, Milwaukee, WI, United States.
Can Urol Assoc J. 2024 Sep;18(9):E253-E260. doi: 10.5489/cuaj.8735.
Despite recent consensus guidelines, there is substantial variability in the management of pheochromocytomas. Our study aimed to characterize the current state of perioperative pheochromocytoma management by Canadian surgeons.
A 23-item online survey was sent to Canadian surgeons who perform adrenalectomies for pheochromocytoma. We assessed personal and institutional practices, including preoperative and postoperative management.
National response rate was 51.8%. Surgeons from nine provinces responded; the majority were general surgeons (70.4%). Reviewing pheochromocytoma patients at a multidisciplinary tumor board was not routine practice (12%) and only 42.3% consistently referred patients for genetic testing. Preoperative α- and β-blockade at half of the respondent institutions were performed by endocrinology alone (53.8%), with the other half employing a multidisciplinary approach. Half of respondents admitted their pheochromocytoma patients to hospital prior to the day of surgery. Postoperatively, 11.5% of respondents routinely admitted their patients to the intensive care unit (ICU) for monitoring based on personal preference or institutional convention. Multivariate analyses found no significant relationships between demographics or preoperative factors and perioperative management.
Perioperative surgical management of patients undergoing adrenalectomy for pheochromocytoma was highly variable across Canada. Less than half of respondents routinely refer patients for genetic testing, despite recent practice guidelines. Surgeon preference and institutional convention are the main drivers behind preoperative admission and routine postoperative ICU admission, despite a lack of evidence to support this practice.
尽管最近有了共识性指南,但嗜铬细胞瘤的管理仍存在很大差异。我们的研究旨在描述加拿大外科医生对嗜铬细胞瘤围手术期管理的现状。
向加拿大进行嗜铬细胞瘤肾上腺切除术的外科医生发送了一份包含23个项目的在线调查问卷。我们评估了个人和机构的做法,包括术前和术后管理。
全国回复率为51.8%。来自九个省份的外科医生做出了回应;大多数是普通外科医生(70.4%)。在多学科肿瘤委员会审查嗜铬细胞瘤患者并非常规做法(12%),只有42.3%的医生始终将患者转诊进行基因检测。一半的受访机构术前α和β受体阻滞剂仅由内分泌科进行(53.8%),另一半采用多学科方法。一半的受访者承认他们的嗜铬细胞瘤患者在手术前一天就入院了。术后,11.5%的受访者根据个人偏好或机构惯例将患者常规收入重症监护病房(ICU)进行监测。多变量分析发现人口统计学或术前因素与围手术期管理之间没有显著关系。
在加拿大,接受嗜铬细胞瘤肾上腺切除术患者的围手术期外科管理差异很大。尽管有最近的实践指南,但不到一半的受访者常规将患者转诊进行基因检测。尽管缺乏证据支持这种做法,但外科医生的偏好和机构惯例是术前入院和术后常规入住ICU的主要驱动因素。